TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20% bone marrow blasts at the time of related donor marrow or stem cell transplantation or at relapse post transplant.~* Willing to undergo a skin biopsy and either a leukodepletion apheresis or an additional marrow aspiration.~* Stem cell or marrow donor willing to have apheresis for T-Cell collection.~* Written voluntary informed consent must be obtained from patient and donor.~Exclusion Criteria:~* Medical, social or psychologic factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure.~* AML French-American-British (FAB) subtype M3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Apheresis + Transplant (Type: EXPERIMENTAL): Skin biopsy \& either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed adrenocortical carcinoma in Stage III or IV and incurable by surgery Bidimensionally measurable disease~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Hematopoietic: WBC at least 4,000/mm3 Absolute granulocyte count at least 2,000/mm3 Platelet count at least 150,000/mm3 Prothrombin time and partial thromboplastin time no greater than upper limit of normal (ULN) Hepatic: SGOT and alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 50 mL/min Serum creatinine no greater than ULN Other: No second malignancy within 5 years except adequately treated basal cell or squamous cell carcinoma of the skin,in situ carcinoma of the cervix, or other cancer for which patient has been disease free for 5 years Not pregnant or nursing Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy At least 4 weeks since prior biologic therapy (one regimen only) Chemotherapy: No concurrent chemotherapy At least 4 weeks since prior mitotane No other prior chemotherapy allowed Endocrine therapy: At least 6 weeks since prior hormonal therapy No concurrent hormonal therapy Radiotherapy: At least 4 weeks since prior radiation therapy (to less than 25% of bone marrow) No concurrent radiation therapy Surgery: Prior surgery allowed in relapsed patients with no other prior treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suramin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation~* Men and women aged ≥ 25 - 80 (included) years of age~* Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline~* Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>2L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for respiratory failure~* Confirmed infection with COVID-19 by any acceptable test available/utilized at each site~* Private insurance or government support (through NHS or other)~Exclusion Criteria:~* Pregnancy or breast feeding;~* Refusal or inability to practice contraception regardless of the gender of the patient;~* ALT and/or AST \> 5 x ULN~* Known, active auto-immune disease;~* Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing;~* Patients with past history of Solid Organ transplant.~* Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load.~* Patients whose respiratory condition is showing significant deterioration as indicated by:~* requirement for a persistent and sustained increase in inspired oxygen concentrations of 20% or more over the past 24 hours to maintain SpO2 at greater than or equal to 88% (this 20 % limit does not apply to O2 delivered by nasal canula)~* or need for invasive mechanical ventilation~* Patients with chronic kidney dialysis~* Patients showing an increase of the NEWS2 score by more than 6 points during the screening / baseline period (48 to 72 hrs prior to first administration)~* Patients with a SOFA score ≥ 9 at baseline~* Patients with a BMI \> 40~* Patients with baseline Rockwood Clinical Frailty Scale ≥ 6.(assessed as patient or proxy 4-week recall of chronic health and frailty status prior to COVID infection)~* Patients under guardianship

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYT107 (Type: EXPERIMENTAL): Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
- Saline (Type: PLACEBO_COMPARATOR): Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically-confirmed breast cancer (operable, locally advanced or inflammatory)~2. Age less than 70 years~3. Female patient~4. Tumor size 2 cm at ultrasound examination.~5. ER-negative tumors defined according to immunohistochemistry (i.e. \< 10% of positive cells after immunostaining).~6. Multifocal and multicentric breast tumors are allowed if all foci are ER-negative.~7. Fixed and frozen samples from the primary tumor, obtained before treatment with epirubicin, must be available for evaluation of biological markers (topo II alpha gene and protein, HER-2 gene, p-53 gene, oligonucleotides microarrays).~8. Written informed consent before study registration.~9. Performance status 0 or 1 (ECOG scale)~10. Normal CBC, hepatic and renal functions~11. Normal left ventricular ejection fraction by echocardiography or muga scan~12. Negative pregnancy test for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal measures to avoid pregnancy during treatment.~Exclusion Criteria:~1. Metastatic breast cancer~2. Serious medical conditions like:~   1. congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled arrhythmias.~  2. history of significant neurologic or psychiatric disorders~  3. active uncontrolled infection~  4. active peptic ulcer, unstable diabetes mellitus~3. Concomitant contralateral invasive breast cancer~4. Concurrent treatment with hormonal replacement therapy~5. Concurrent treatment with any other anti-cancer therapy~6. Previous treatment with anthracyclines for breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell Based Therapy of Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven progressive metastatic or locally advanced breast cancer~* No standard treatment indicated~* Age: \> 18~* WHO-Performance Status 0-1~* At least tone measurable tumor lesions according to the RECIST criteria.~* Expression of the HLA-A2 tissue type~* Life expectancy more than 3 months~* Acceptable CBC and blood chemistry results~* Written informed consent~Exclusion Criteria:~* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin).~* Patients with metastatic disease in the central nervous system (CNS).~* Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.~* Patients with acute or chronic infection including HIV, hepatitis and tuberculosis.~* Patients who are pregnant.~* Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.~* Patients who receive corticosteroids or other immunosuppressive agents.~* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Current indications for primary total hip arthroplasty utilising a cemented femoral component. These include pain, deformity and loss of function which are not responsive to medical treatment~Exclusion Criteria:~i) Revision Total Hip Arthroplasty ii) Rheumatoid arthritis iii) Age greater than 80 years at time of surgery iv) Age less than 60 years at time of surgery v) Previous hip joint sepsis vi) Obesity vii) Patient likely to remain housebound once rehabilitation is complete

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1) Ultima LX Collared Stem - Non-Polished/Blasted Finished (Type: ACTIVE_COMPARATOR): A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
- 2) Ultima LX Collared Stem - Polished Finished (Type: ACTIVE_COMPARATOR): A collared polished finished cementless femoral component for use in total hip replacement.
- 3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished (Type: ACTIVE_COMPARATOR): A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
- 4) Ultima LX Collarless Stem - Polished Finished (Type: ACTIVE_COMPARATOR): A collarless polished finished cementless femoral component for use in total hip replacement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Any laceration caused by trauma and involving the skin of the upper and/or lower eyelid.~* Must be able to understand and sign an informed consent when applicable and Health Insurance Portability and Accountability Act(HIPAA) form that has been approved by an Institutional Review Board (IRB) or follow standard informed consent procedure of the IRB~Exclusion Criteria:~* Eyelid lacerations that include avulsion or missing eyelid tissue~* Patients with known hypersensitivity to octyl-2-cyanoacrylate or previous poor reaction to octyl-2-cyanoacrylate~* Eyelid lacerations resulting in necrosis or ischemia of tissue prior to repair~* Patients who demonstrate intoxication or mental status changes that would make them unfit to provide informed consent for repair

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-absorbable suture skin closure (Type: EXPERIMENTAL): The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
- Absorbable suture skin closure (Type: EXPERIMENTAL): The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
- Tissue Adhesive skin closure (Type: EXPERIMENTAL): The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gave an informed consent~* Forced expiratory volume in 1 second \< 80% predicted~* Forced expiratory volume in 1 second / Forced vital capacity \< 70%~* No exacerbation in the last 4 weeks~* Current or ex-smoker~* Smoking history of at least 10 pack/year~* Body mass index of at least 25 kg/m2~* Waist circumference of at least 94 cm~* Fasting blood triglycerides of at least 1.7 mmol/L~Exclusion Criteria:~* Any significant pulmonary pathology other than COPD~* Under oxygen therapy more than 12 hours per day~* More than 2 exacerbation episodes in the last 12 months~* The patient is currently participating to the active phase of a rehabilitation program~* Patient has been under roflumilast therapy prior to enrollment~* Unstable hypertriglyceridemia or hypercholesterolemia~* Under diabetes therapy (hypoglycemic agent or insulin)~* Cancer history in the last 5 years (except basal cell carcinoma)~* Moderate or severe hepatic impairment~* Used prednisone or systemic corticosteroids in the last 4 weeks

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: EXPERIMENTAL): Roflumilast 500 mcg, once daily for 6 months
- Placebo pill (Type: PLACEBO_COMPARATOR): Placebo pill, once daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven adenocarcinoma of the stomach.~* Surgical resectable carcinoma (T1-4b, N1-3) (table 1)~* Pathological proven peritoneal metastases~* Peritoneal Cancer Index (PCI) ≤12~* WHO performance status 0,1 or 2 and ASA 1-3~* Age ≥ 18~* Written informed consent~Exclusion Criteria:~* Distant metastases other than peritoneal metastases~* Siewert type I/II gastro-esophageal junction tumor 22.~* Peritoneal carcinomatosis as a presentation of recurrent disease~* Pregnancy~* Any contraindication to cisplatin, e.g.~  * Hypersensitivity~ * HIV infection~ * inadequate bone marrow function (ANC \<1.5x109/L or Platelets \<100x109/L)~ * inadequate hepatic function (\>1.5 x ULN, ALAT and ASAT \>2.5 x ULN)~ * inadequate renal function (Creatinine clearance \<50 ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study population (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 19-100~* scheduled to undergo general ENT or Orthopedic Surgery~* diagnosis of obstructive sleep apnea as confirmed by sleep study or deemed high risked for obstructive sleep apnea by clinical predictors (greater than 4 clinical predictors of obstructive sleep apnea as described by STOP BANG ).~Exclusion Criteria:~* positive pregnancy test~* ASA \> III~* history of alcohol or narcotic abuse in last 90 days~* significant cardiovascular or respiratory disease (baseline oxygen saturation below 92%)~* significant psychiatric or neurologic disease~* history of significant hepatic or renal disease (baseline creatinine\>1.5)~* history of allergy or contraindication to anesthetic agents or ketamine including patients with increased ICP~* increased IOP~* severe arrhythmias~* history of delirium~* history of hallucinations~* history of psychosis~* history of uncontrolled seizures~* potential risk for malignant hyperthermia (family history)~* history of difficult intubation that would preclude standard induction of anesthesia~* prisoners~* persons who are mentally impaired~* non-English speakers

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): OSA patients will receive standard inhaled anesthesia with normal saline infusion
- Ketamine Group (Type: ACTIVE_COMPARATOR): OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. English-speaking adults~2. Age 18-70~3. Survivor of a variety of traumas (e.g., motor vehicle and accidents, burns and others injuries, combat, World Trade Center attack, etc.)~4. Diagnosed with PTSD~5. In good health. For persons with chronic injuries/conditions related to their accidents, good health is defined as the injury being in a state of stabilization and able to attend weekly outpatient sessions.~Exclusion Criteria:~1. Current organic mental disorder~2. Schizophrenia or symptoms of psychosis/delusions~3. Bipolar disorder~4. Current substance abuse or dependence~5. Active suicidal/homicidal ideation, intent, or plan~6. Use of pacemaker~7. Significant health impairment, including renal disease~8. Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication~9. Hypersensitivity to cycloserine~10. History of seizures~11. Pregnant or currently trying to conceive, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- D-cycloserine (Type: EXPERIMENTAL): 100 mg on days of therapy session
- Placebo (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Implementation of a Protocol Utilizing Adaptive CRT in a Normal AV Conduction, CRT Non-Response Population at Generator Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Normal AV conduction (SAV\<220 ms or PAV\<270 MS)~* Left Bundle Branch Block (defined as \> or = to 140 ms (male) or \> or = 130 (female), QR or rS in leads V1 and V2, and Mid QRS notching or slurring in v 2 of leads V1, V2, V5, V6 and I and aVL.)~* Patient and/or physician assessment or unchanged or worsened heart failure status at the time of recommended replacement time (RRT) for previous CRT device.~* Sinus Rhythm at the time of enrollment~Exclusion Criteria:~* Moderate to severe Aortic Stenosis~* Moderate to severe Mitral Regurgitation~* Patient age \<18 years old~* AF burden \>15%~* Severe pulmonary disease requiring supplemental oxygen use~* ESRD~* System Modification at RRT Generator Changeout~* AdaptivCRT prior to enrollment~* Expected patient longevity \< 1 year~* Persistant or chronic atrial fibriliation~* Women who are pregnant or who plan to become pregnant during the clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adaptiv CRT (Type: OTHER): Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues